Abstract:Objective To analyze the monitoring resistance results of carbapenem-resistant Enterobacteriaceae in Huludao Central Hospital. Methods The carbapenem Enterobacteriaceae bacteria detection, distribution and drug resistance were tested using EDTA collaborative test, modified Hodge test, Kirby-Bauer method (KB method) combining with Phoenix-100 full-automatic bacterial identification/drug susceptibility system in Huludao Central Hospital from January 2017 to December 2019. Results From January 2017 to December 2019, a total of 9220 strains of Enterobacteriaceae bacteria were isolated, of which 510 were carbapenem Enterobacteriaceae, and the total detection rate was 5.53% (510/9220). The three-year detection rates in 2017, 2018, and 2019 were 32.55%(166/510), 34.51%(176/510)and 32.94%(168/510), respectively, and the difference was not statistically significant (P>0.05). Among 510 carbapenem Enterobacteriaceae, the main specimen was sputum, accounting for 74.90% (382/510). The other specimen sources were 3 strains from pleural fluid specimens (0.59%), 5 from bile specimens (0.98%), 7 from secretions specimens (1.37%), 9 from ascites specimens (1.76%), 11 strains from drainage fluid specimens (2.16%), 20 strains from urine specimens(3.92%), 22 strains from catheter tip specimens (4.31%), 51 from blood specimens (10.00%). From 2017 to 2019, the bacterial strains of carbapenem Enterobacteriaceae resisted against the commonly used antibacterial drugs such as Meropenem, Imipenem, Aztreonam, Cefepime, Cefotaxime, Ceftazidime, Cefazolin, Piperacillin/Trizobacte, and Cefoperazone/Sulbactam. The strains were sensitive to Tigecycline and polymyxin. Conclusion The infection rate of carbapenem Enterobacteriaceae in the hospital is relatively high. The most common strain is Klebsiella pneumoniae, which is resistant to most antibacterial drugs. It is resistant to Tigecycline, Polymyxin, Cotrimoxazole, Amikacin, and Gentamicin to a certain degree. When choosing drugs in clinic, the corresponding antibacterial drugs should be selected based on the actual situation.
张曼佳. 2017~2019年葫芦岛市中心医院耐碳青霉烯肠杆菌科细菌耐药性监测结果分[J]. 中国当代医药, 2021, 28(12): 154-156转160.
ZHANG Man-jia. Analysis of the surveillance results of carbapenem-resistant Enterobacteriaceae drug resistance in Huludao Central Hospital from 2017 to 2019. 中国当代医药, 2021, 28(12): 154-156转160.
Khare V,Gupta P,Haider F,et al.Study on MICs of tigecycline in clinical isolates of carbapenem resistant Enterobacteriaceae (CRE) at a tertiary care centre in north India[J].J Clin Diagn Res,2017,11(3):18-21.
Rosa JF,Rizek C,Marchi AP,et al.Clonality,outermembrane proteins profile and efflux pump in KPC producing Enterobacter sp. in Brazil[J].BMC Microbiol,2017,17(1):69-78.
[5]
TadaT,TsuchiyaM,ShimadaK,etal.Disseminationofcarbapenem-resistant Klebsiella pneumoniae clinical isolates with various combinations of carbapenemases (KPC-2,NDM-1,NDM-4,and OXA-48) and 16S rRNA methylases (RmtB and RmtC)in Vietnam[J].BMC Infect Dis,2017,17(1):467-473.
[6]
Stoesser N,Sheppard AE,Peirano G,et al.Genomic epidemiology of global Klebsiella pneumoniae carbapenemase(KPC)-producing Escherichia coli[J].Sci Rep,2017, 7(1):5917-5923.